Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1Other solid neoplasm 1Genitourinary 1Dermatologic 1

Conditions

Sarcoma 4Gliosarcoma 4Glioblastoma 4Brain Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Ovarian Neoplasms 2Oligodendroglioma 2Neoplasm Metastasis 2Melanoma 2Liposarcoma 2Endometrial Neoplasms 2Carcinosarcoma 2Carcinoma, Transitional Cell 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Soft Tissue Neoplasms 1Sarcoma, Alveolar Soft Part 1Rhabdomyosarcoma 1Recurrence 1Prostatic Neoplasms 1Platinum-Refractory Fallopian Tube Carcinoma 1Pharyngeal Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neurofibromatosis 2 1Neoplasms, Mesothelial 1Neoplasms 1

Interventions

Taxes 1Immunoglobulin G 1Disulfides 1Bevacizumab 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cervical Adenocarcinoma × Immunoglobulin G × Sarcoma × Clear all
NCT02020707 2024-07-26

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Mayo Clinic

Phase 1 Completed
43 enrolled
DermatologicGenitourinaryGynecologicOther solid neoplasmSarcoma

Cervical Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡